1,829 results on '"Wright, A."'
Search Results
2. Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)
3. An LGR6 frameshift variant abrogates receptor expression on select leukocyte subsets and is associated with viral infections
4. Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trial
5. Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis
6. Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study
7. Preservation of the fecal microbiome is associated with reduced severity of graft-versus-host disease
8. Noncoding mutations drive persistence of a founder preleukemic clone which initiates late relapse in T-ALL
9. Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma
10. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors
11. Rare and low-frequency variants and their association with plasma levels of fibrinogen, FVII, FVIII, and vWF
12. Discovery of a CD10-negative B-progenitor in human fetal life identifies unique ontogeny-related developmental programs
13. Motive and opportunity: MYCrearrangements in high-grade B-cell lymphoma with MYCand BCL2rearrangements (an LLMPP study)
14. A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome
15. Preservation of the fecal microbiome is associated with reduced severity of graft-versus-host disease
16. Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia
17. TLR9-Selective Therapeutic Targeting of MDS Clones with a CpG Payload-Delivery Strategy
18. Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CML
19. Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma
20. Mito-protective autophagy is impaired in erythroid cells of aged mtDNA-mutator mice
21. Redefining nonmeasurable multiple myeloma using mass spectrometry
22. TLR9-Selective Therapeutic Targeting of MDS Clones with a CpG Payload-Delivery Strategy
23. Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CML
24. Systematically Interrogating Downstream Regulation Mechanisms of HOXA9 in MLL-r Leukemia Via Functional Noncoding CRISPR Screens
25. Prediction of Early Disease Progression at 24 Months (POD24) Using Pre-Treatment Biopsies from Patients with Follicular Lymphoma (FL) Treated with Immunochemotherapy (IC)
26. A Dual-Antigen Targeting, Hypoimmune Allogeneic CAR T to Evade Innate and Adaptive Immune Rejection and Overcome Antigen Escape
27. CD8-Targeted, Integrating Viral Vectors Transduce Resting T Cells and Enable Extracorporeal Delivery (ECD) for Rapid CAR T Cell Therapies
28. Pain Attitudes in Adults with Sickle Cell Disease: A Mixed Methods Study
29. Inhibition of CDC7 with Sgr-2921 in AML Models Results in Enhanced DNA Damage and Anti-Leukemic Activity As Monotherapy and in Combination with Standard of Care Agents
30. Multi-Institutional Review of Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas
31. Assessing the Recovery Process after a Vaso Occlusive Crisis
32. Self-Efficacy and Stigma in Adults with Sickle Cell Disease: An Import Study Analysis
33. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma
34. Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma
35. SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage
36. Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior
37. A Dual-Antigen Targeting, Hypoimmune Allogeneic CAR T to Evade Innate and Adaptive Immune Rejection and Overcome Antigen Escape
38. Multi-Institutional Review of Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas
39. Systematically Interrogating Downstream Regulation Mechanisms of HOXA9 in MLL-r Leukemia Via Functional Noncoding CRISPR Screens
40. Assessing the Recovery Process after a Vaso Occlusive Crisis
41. CD8-Targeted, Integrating Viral Vectors Transduce Resting T Cells and Enable Extracorporeal Delivery (ECD) for Rapid CAR T Cell Therapies
42. Pain Attitudes in Adults with Sickle Cell Disease: A Mixed Methods Study
43. Inhibition of CDC7 with Sgr-2921 in AML Models Results in Enhanced DNA Damage and Anti-Leukemic Activity As Monotherapy and in Combination with Standard of Care Agents
44. Self-Efficacy and Stigma in Adults with Sickle Cell Disease: An Import Study Analysis
45. Prediction of Early Disease Progression at 24 Months (POD24) Using Pre-Treatment Biopsies from Patients with Follicular Lymphoma (FL) Treated with Immunochemotherapy (IC)
46. HIV-1 infection of human macrophages directly induces viperin which inhibits viral production
47. Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia
48. Redefining nonmeasurable multiple myeloma using mass spectrometry
49. Down-regulation of BLIMP1α by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas
50. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.